Showing 1136 results
-
Ad hoc release /Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing…
-
Press release /SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
-
Press release /Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only…
-
Press release /Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has…
-
Press release /Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon…
-
Press release /Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
-
Press release /Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
-
Press release /New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Press release /Company leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in…
-
Press release /Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…